Clinical and immunological features of hepatitis C treatment-associated dermatitis in 36 prospective cases.
Lübbe
J
J
Kerl
K
K
Negro
F
F
Saurat
J-H
JH
D000998:Antiviral Agents / Q000009:adverse effects*; D003875:Drug Eruptions / Q000209:etiology*; D004359:Drug Therapy, Combination; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects; D011092:Polyethylene Glycols / Q000009:adverse effects; D011446:Prospective Studies; D011994:Recombinant Proteins; D012254:Ribavirin / Q000009:adverse effects
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a